The Great Peptide Debate with Martin Shkreli & Max Marchione

March 23, 2026

AI Summary

5 min read

Martin Shkreli, self-described representative of the pharmaceutical industry, debates Max Marchione of Superpower on the surge in peptide use for wellness and optimization. Shkreli views most peptides as overhyped scams driven by distrust and self-experimentation, insisting on rigorous FDA trials. Marchione, a former skeptic turned advocate after consulting dozens of doctors, argues select peptides show promise via real-world use and should be legalized through compounding to reduce gray-market risks.

Peptides Defined and GLP-1 Success

Peptides are short chains of amino acids naturally occurring in the body, unlike synthetic small molecules designed to block biology. Shkreli notes pharma historically avoids peptides due to poor properties like short half-lives, favoring small molecules or antibodies. Yet GLP-1 receptor agonists like Ozempic—peptides modified for longer action—represent a breakthrough, transforming obesity and diabetes treatment and generating massive revenue. Marchione highlights this as proof peptides belong in the toolkit, especially with injecting normalized by GLP-1s and AI aiding discovery. Both agree FDA-approved GLP-1s work but diverge on off-label or unapproved ones.

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

Listen to Audio Summary Open in App

Never miss an episode of TBPN

Get every new episode summarized in your inbox — free, ~5 minutes to read.

No spam. Unsubscribe anytime.

What you'll learn

1 (00:00) **Introductions and Core Theses** - Martin Shkreli (Pharma Bro) opposes peptide craze as psychologically driven; Max Marchione (Superpower) converted skeptic now sees peptides as exciting for wellness with research needs
2 (02:30) **Defining Peptides and Debate Scope** - Narrowing to off-label use like Wolverine stack vs prescribed Ozempic, peptides as natural body-derived vs small molecules that block biology
3 (05:11) **Risks of Self-Experimentation and Grey Market** - Concerns over unverified Chinese peptides and private companies profiting from unproven stacks
4 (06:07) **Intellectual Property and Retatrutide** - Martin condemns IP theft of Eli Lilly's Retatrutide by Chinese sources as harmful to US innovation
5 (08:37) **Compounding Categories and Legalization Debate** - RFK's push to recategorize 14 peptides for compounding; Max argues legalization minimizes grey market risks
6 (09:32) **BPC-157 Deep Dive: Pro Arguments** - Max cites thousands of doctors prescribing for 10-20 years, millions of patients with life-changing anecdotes (e.g., pain relief, autoimmune remission)
7 (12:12) **BPC-157 Counter: Martin's Scam Claim** - Martin calls BPC-157 biggest scam; originated from unverified gastric juice claim, no sequence match, failed PLIVA trials

+ Full timestamped outline available in the app

Show Notes

This is our full interview with Martin Shkreli and Max Marchione, recorded live on TBPN.

We discuss the sharp divide between biotech orthodoxy and the rising peptide movement, unpack the fight over whether compounds like BPC-157 are dangerous gray-market hype or promising under-researched tools with real-world patient impact, and debate whether the FDA should hold the line on traditional evidence standards or adapt to a world where off-label experimentation, compounding, and anecdotal outcomes are already forcing the issue.

TBPN is a live tech talk show hosted by John Coogan and Jordi Hays, streaming weekdays from 11–2 PT on X and YouTube, with full episodes posted to podcast platforms immediately after.

Described by The New York Times as “Silicon Valley’s newest obsession,” TBPN has recently featured Mark Zuckerberg, Sam Altman, Mark Cuban, and Satya Nadella.

TBPN.com is made possible by:
Ramp - https://Ramp.com
AppLovin - https://axon.ai
Cisco - https://www.cisco.com
Cognition - https://cognition.ai
Console - https://console.com
CrowdStrike - https://crowdstrike.com
ElevenLabs - https://elevenlabs.io
Figma - https://figma.com
Fin - https://fin.ai
Gemini - https://gemini.google.com
Graphite - https://graphite.com
Gusto - https://gusto.com/tbpn
Kalshi - https://kalshi.com
Labelbox - https://labelbox.com
Lambda - https://lambda.ai
Linear - https://linear.app
MongoDB - https://mongodb.com
NYSE - https://nyse.com
Okta - https://www.okta.com
Phantom - https://phantom.com/cash
Plaid - https://plaid.com
Public - https://public.com
Railway - https://railway.com
Ramp - https://ramp.com
Restream - https://restream.io
Sentry - https://sentry.io
Shopify - https://shopify.com
Turbopuffer - https://turbopuffer.com
Vanta - https://vanta.com
Vibe - https://vibe.co

Follow TBPN:
https://TBPN.com
https://x.com/tbpn
https://open.spotify.com/show/2L6WMqY3GUPCGBD0dX6p00?si=674252d53acf4231
https://podcasts.apple.com/us/podcast/technology-brothers/id1772360235
https://www.youtube.com/@TBPNLive